OXFORD, UNITED KINGDOM - 12 JUNE 2025. Beckley Psytech Ltd, a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announces that clinical and micro-phenomenology data from its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder (AUD) will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) from 14 - 18 June 2025 in New Orleans. The findings will be shared by John Marsden, Professor of Addiction Psychology and Head of the Addictions Department at King’s College London, and Dr. Anya Ermakova, Senior Manager - Clinical Scientist at Beckley Psytech during a symposium session on Tuesday 17th June at 10:45am CDT.
In the open-label Phase IIa study, which took place at King’s College London and Clerkenwell Health in the UK, 12 patients with moderate-to-severe AUD were given a single dose of BPL-003 alongside relapse prevention cognitive behavioural therapy. Topline findings shared in January 2025 showed that treatment with BPL-003 could induce meaningful and sustained reductions in alcohol use and Heavy Drinking Days (HDDs) for up to 3 months following a single dose, with the mean number of alcohol units per day decreasing from 9.3 in the 12 weeks prior to dosing to 2.2 at 12 weeks post-dosing. The mean percentage of Heavy Drinking Days also dropped from 56% in the pre-dose period to 13% at the end of the study, whilst the mean number of abstinent days increased from 33% to 81%. Furthermore, 50% of participants remained completely abstinent during the 12-week follow-up period following a single dose.
A symposium on psychedelics at CPDD will include new insights into the efficacy, safety and tolerability profile of BPL-003 as a potential treatment for AUD, as well as micro-phenomenological analyses of participants’ subjective experiences while undergoing the treatment.
Professor Marsden commented: “These encouraging preliminary findings contribute to the growing body of evidence supporting the potential role of psychedelics in treating substance use disorders. Results from this Phase IIa study provide a foundation for further investigation of intranasal 5-MeO-DMT in combination with relapse prevention therapy for alcohol use disorder.”
"I am excited to share insights from our study with experts attending CPDD.” added Dr. Anya Ermakova, Senior Manager - Clinical Scientist at Beckley Psytech. “Integrating micro-phenomenological methods into clinical research can help researchers better understand the lived experiences of those undergoing treatment with compounds like 5-MeO-DMT."
The CPDD Annual Scientific Meeting is the longest-running and most prestigious scientific conference on substance use and addiction, bringing together researchers, clinicians and policymakers from across the globe.
For more information please contact: Charlotte Chorley, Communications Lead, at info@beckleypsytech.com
About Beckley Psytech - www.beckleypsytech.com
Beckley Psytech Ltd is a private, clinical-stage biopharmaceutical company developing effective, rapid-acting and accessible medicines for people living with difficult-to-treat mental health conditions. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, Beckley Psytech combines cutting-edge science with deep drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden mental health conditions have on individuals, healthcare systems and society.
About BPL-003
BPL-003 is Beckley Psytech’s synthetic, proprietary intranasal formulation of 5-MeO-DMT benzoate, administered via a nasal spray device used in a previously approved drug product. BPL-003 is designed to deliver rapid and durable effects from a single dose, with a short time in the clinic and is being investigated as a potential therapy for treatment resistant depression (TRD) and for alcohol use disorder (AUD). BPL-003 is covered by granted US, UK and European composition-of-matter patents, with multiple further claims pending in various jurisdictions.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
